KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Receivables for 16 consecutive years, with $441.3 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 34.23% to $441.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $441.3 million through Dec 2025, up 34.23% year-over-year, with the annual reading at $441.3 million for FY2025, 34.23% up from the prior year.
  • Receivables for Q4 2025 was $441.3 million at Halozyme Therapeutics, up from $346.0 million in the prior quarter.
  • The five-year high for Receivables was $441.3 million in Q4 2025, with the low at $92.1 million in Q4 2021.
  • Average Receivables over 5 years is $234.9 million, with a median of $232.1 million recorded in 2022.
  • The sharpest move saw Receivables soared 313.15% in 2021, then fell 27.49% in 2023.
  • Over 5 years, Receivables stood at $92.1 million in 2021, then soared by 150.85% to $231.1 million in 2022, then grew by 1.79% to $235.2 million in 2023, then soared by 39.77% to $328.8 million in 2024, then surged by 34.23% to $441.3 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $441.3 million, $346.0 million, and $316.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.